Lab21 Sells SC Labs, Assets Acquired by Selah Genomics | GenomeWeb

NEW YORK (GenomeWeb News) – The Cambridge, UK-based personalized diagnostics company Lab 21 said today that it has sold its lab operations in South Carolina to a new entity formed by existing local Lab21 executives who will launch a new company called Selah Genomics.

The sale of the clinical service lab operations in Greenville and Columbia, which Lab21 has run for three years, will remove a loss-making business from the company's books, but will not impact the company's core strategies in the US market.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: weighting scheme increases GWAS power, and more.

Marc Tessier-Lavigne is to be the next president of Stanford University.

Walgreens has given Theranos 30 days to fix its lab issues, the Wall Street Journal reports.

Journals and research funding agencies pledge to enable the sharing of Zika virus research.

Mar
03
Sponsored by
Agilent Technologies

This webinar will discuss the use of a hybrid capture-based FFPE DNA sequencing methodology with the potential for advancing precision oncology studies.